NCT02175758 - Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

July 7, 2014

Primary Completion Date

June 21, 2018

Study Completion Date

September 13, 2018

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF

SOF administered orally once daily

DRUG

RBV

RBV oral solution or capsules will be administered orally in a divided daily dose based on weight

Trial Locations (37)

Unknown

Los Angeles

San Francisco

Washington D.C.

Gainesville

Atlanta

Indianapolis

Baltimore

Boston

New York

Cincinnati

Philadelphia

Nashville

Dallas

Fort Worth

Seattle

Morgantown

Westmead

Melbourne

New Lambton Heights

Brussels

Wuppertal

Berlin

Bologna

Florence

Milan

Padua

San Giovanni Rotondo

Torino

Auckland

Saint Petersburg

Moscow

Novokuznetsk

Saint Petersburg

Tolyatti

Birmingham

Leeds

London